ROSETTA OMICS

About the company

Rosetta Omics pioneers precision medicine through tumor characterization using spatial multiomics, deep mass spectrometry and AI. Their focus is to optimize first-line treatments by matching therapies with patients effectively, starting with liver and colon cancers. They aim to empower oncologists with a transformative tool, enhancing patient care, and cutting costs. Collaborating with pharma and biotech firms, they seek to identify new biomarkers, accelerating therapeutic and diagnostic innovations.

Committed to scientific advancement and patient well-being, Rosetta Omics is reshaping cancer care. Through cutting-edge technologies and comprehensive multiomics analysis, they provide personalized treatment insights for improved outcomes. Rosetta Omics is at the forefront of precision medicine, driven by innovation, collaboration, and a commitment to saving lives.

About the solution

Their biopsy-based predictive test can be integrated within the standard clinical procedure of biopsy collection for diagnostics to assist in the decision-making process. Their services and products can also identify biomarkers of clinical interest and be used to discover new targets for drug development.

Website

Key information

– Therapeutic areas: Oncology, Cancer, Liver cancer, Colon cancer, Precision medicine, AI

– Based in: Paris (FRANCE)

– Employees: 1 – 10

– Created in: 2023

PEP-THERAPY

About the company

Originally spun out from the prestigious Institut Curie and Sorbonne University (Paris, France), PEP-Therapy is a clinical-stage company developing first-in-class peptides as targeted therapies for the treatment of aggressive cancers.

Following promising Phase Ia results, including preliminary signs of efficacy, PEP-Therapy is now performing Phase Ib trials (NCT 04733027) in both Platinum-Resistant Ovarian Cancer and Pancreatic Ductal Adenocarcinoma (PROC and PDAC).

PEP-Therapy is strongly backed by international investors: Seventure Partners, i&i Prague, Italian Angels for Growth (IAG), Doorway, Anaxago, Magna Capital Partners (MCP), BAdGE, and Majoie family.

About the solution

PEP-010, PEP-Therapy’s flagship product, in summary:
– First-in-class bifunctional targeted peptide
– MoA: triggering apoptosis by disruption of Caspase-9/PP2A interaction
– Phase Ia promising results: – Favorable safety and tolerability profiles, RP2D determined in monotherapy and in combination with paclitaxel – Promising signals of antitumor activity
– Phase Ib trials underway (NCT 04733027): multicenter (in partnership with leading clinical oncology centers: Institut Curie, Gustave Roussy)
– Focus on PROC and PDAC (Platinum-Resistant Ovarian Cancer and Pancreatic Ductal Adenocarcinoma) in combination with paclitaxel and gemcitabine
– Indication expansion potential, in solid and in liquid cancers
– Translational biomarkers development ongoing
– Spin-off from the prestigious Institut Curie and Sorbonne University. Backed by international investors.

Website

Key information

– Therapeutic areas: Oncology, Cancer

– Based in: Paris (FRANCE)

– Employees: 1 – 10

– Created in: 2014